ARTICLE | Company News

Procept other research news

March 14, 1994 8:00 AM UTC

The Cambridge, Mass., company, in conjunction with Dana-Farber Cancer Institute and Harvard University, has received a four-year, $3 million grant from the National Cooperative Drug Discovery Group of the NIH to conduct AIDS research focused on CD4, a protein on the surface of T cells that is the primary entry point for HIV.

PRCT is using structure-based drug design to develop small-molecule compounds that bind to CD4 and prevent entry of HIV into T cells. ...